Cellectar Biosciences INC NEW (CLRB) Stock Price

CLRBStock

$2.53−46.06%52W

Market Cap$23.91M

P/E—

PEG Ratio—

Div yield—

Beta0.55

CLRB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-36.63%

Price vs S&P 500 (4W)-6.43%

VGM Score28.10

Book Value / Share (Quarterly)$1.11

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.38

Price vs S&P 500 (YTD)-27.06%

Net Profit Margin (TTM)-24744.44%

EPS (TTM)$-7.41

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-7.41

EPS (Annual)$-8.35

ROI (Annual)-219.69%

Cash / Share (Quarterly)$1.97

ROA (Last FY)-145.48%

EBITD / Share (TTM)$-6.77

ROE (5Y Avg)-157.80%

Operating Margin (TTM)-11300.00%

Cash Flow / Share (Annual)$-5.45

P/B Ratio4.20x

P/B Ratio (Quarterly)2.28x

Net Income / Employee (Annual)$-1,981,000

EV / Revenue (TTM)127.47x

Net Interest Coverage (TTM)-10.07x

ROA (TTM)-153.18%

EPS Incl Extra (Annual)$-8.35

Current Ratio (Annual)2.96x

Quick Ratio (Quarterly)1.71x

3-Month Avg Trading Volume0.75M

52-Week Price Return-46.06%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.46

P/S Ratio (Annual)198.20x

Asset Turnover (Annual)0.01x

52-Week High$6.52

EPS Excl Extra (Annual)$-8.35

CapEx CAGR (5Y)-37.16%

Tangible BV CAGR (5Y)11.30%

26-Week Price Return-24.70%

Quick Ratio (Annual)2.78x

13-Week Price Return-19.43%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.90x

Enterprise Value$11.47M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-24.66%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-22270.00%

Cash / Share (Annual)$3.11

3-Month Return Std Dev56.26%

Net Income / Employee (TTM)$-1,894,600

ROE (Last FY)-219.69%

Net Interest Coverage (Annual)-13.03x

EPS Basic Excl Extra (Annual)$-8.35

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.41

ROI (TTM)-264.79%

P/S Ratio (TTM)220.22x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.65

Price vs S&P 500 (52W)-64.61%

Year-to-Date Return-14.24%

5-Day Price Return0.40%

EPS Normalized (Annual)$-8.35

ROA (5Y Avg)-174.40%

Net Profit Margin (Annual)-22270.00%

Month-to-Date Return-1.56%

Cash Flow / Share (TTM)$-3.44

EBITD / Share (Annual)$-8.73

Operating Margin (Annual)-10170.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.80%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-7.41

P/TBV (Quarterly)5.65x

P/B Ratio (Annual)1.26x

Pretax Margin (TTM)-24744.44%

Book Value / Share (Annual)$2.34

Price vs S&P 500 (13W)-21.38%

Beta0.55x

Revenue / Share (TTM)$0.00

ROE (TTM)-264.79%

52-Week Low$2.20

vGradeD

mGradeD

vgmGradeD

CLRB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.52	-$0.57	-9.62%(-$0.05)
Q1 2026	May 14, 2026	-$1.89	-$1.33	+29.44%(+$0.55)
Q4 2025	Mar 4, 2026	-$1.23	-$0.53	+56.73%(+$0.70)
Q3 2025	Nov 13, 2025	-$2.53	-$1.41	+44.21%(+$1.12)
Q2 2025	Aug 14, 2025	-$3.70	-$3.39	+8.38%(+$0.31)

CLRB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.22

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
CLRBCellectar Biosciences INC NEW	D	—	D	$2.53
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Cellectar Biosciences INC NEW

Cellectar Biosciences is a clinical-stage biopharmaceutical company developing cancer therapeutics using its proprietary phospholipid drug conjugate (PDC) delivery platform. The company's PDC technology is designed to selectively target cancer cells, potentially offering improved efficacy with reduced off-target toxicity compared to conventional approaches. Cellectar is leveraging this platform to build a pipeline of oncology drugs aimed at addressing unmet patient needs in cancer treatment.